Skip to content

2026 CMTA Patient & Research Summit Recap: Day 2

Day 2 of the 2026 CMTA Patient & Research Summit in San Francisco was focused on CMT research, from discovery to delivery, and clinical trials in progress. This research is directed through CMTA’s Strategy To Accelerate Research (STAR). Here are the highlights.  

If you missed it, read our Day 1 recap for the keynote and more from Saturday.  

Keynote address 

Cara Leath, CMT Community Member  

Cara Leath, who lives with CMT1B, opened STAR Sunday with her journey from diagnosis to clinical trial participant. Since her 2014 diagnosis, she has taken part in natural history studies, biomarker research, and, in summer 2025, NMD Pharma’s Phase 2 trial of ignaseclant. She shared four calls to action: 

 1. Reach out every time: Contact the study team even if you’re not sure you qualify. Cara almost counted herself out of the trial she ended up joining. 

2. Push past fear: Study drugs are held to high safety standards, and participants are closely monitored. “Every drug you have ever taken was new once,” she said. 

3. See it through: Even if you might get a placebo, finishing a trial is the only way to learn whether a treatment works. 

4. Find your role: Everyone can help, whether by spreading the word about studies or setting up a small recurring donation to the CMTA.  

Cara closed by inviting everyone to help rewrite the ending of the CMT story by taking an active role in research.  

STAR research welcome: CMTA driving progress from drug discovery to drug delivery 

Katherine Forsey, PhD, Chief Research Officer, CMTA 

Katherine Forsey explained that CMT affects about 1 in 2,500 people and covers more than 175 genetic subtypes. For more than 30% of the community, the genetic cause of their CMT is still unknown. Because one treatment is unlikely to help everyone, the CMTA invests across many subtypes and approaches through STAR’s four pillars: 

1. Discovery: Finding the genetic causes of CMT and how they affect cells. 

2. Developing treatments: Testing therapies that target the root cause of CMT or pathways shared across subtypes. 

3. Delivery: Getting treatments to the right cells, one of the biggest challenges in CMT treatment development. 

4. Clinical trial readiness: Building the patient networks, natural history data and clinical trial sites needed to test new treatments. 

Over 18 years, the CMT community has raised more than $38.5 million for STAR. “Clinical trials in CMT are happening today, not someday,” she said. Every patient with CMT benefits from the research CMTA is funding. Katherine invited the entire CMT community to join with us as we push hard to get the first treatments across the line.  

Our commitment to investing in clinical trial readiness: CMTA–INC partnership 

Michael Shy, MD, Director of the Neuromuscular and Neurogenetics Divisions & Professor of Neurology and Pediatrics, University of Iowa 

Sue Bruhn, PhD, Chief Executive Officer, CMTA 

The session opened with Dr. Michael Shy receiving the 2026 CMTA Lifetime Achievement Award. Sue Bruhn then led a conversation with him about the Inherited Neuropathy Consortium (INC), which Dr. Shy helped launch in 2009. The INC has grown to 26 sites worldwide that follow more than 10,000 people with CMT using the same set of measures. This helps researchers understand how each subtype progresses and whether a treatment is working. When National Institutes of Health funding ended, CMTA stepped in to keep the Consortium going. With genetic therapies and other treatments now in clinical trials, Dr. Shy called this “the most exciting time in history” for CMT research. 

Targeting the root cause of CMT  

Luke Judge, MD, PhD, Neonatologist, UCSF Benioff Children’s Hospital 

Catherine Illingworth, Founder & Chief Executive Officer, Kylix Bio 

Luke Judge explained how genetic therapies aim to fix CMT at the DNA level. Funded by CMTA, his lab is using CRISPR gene editing in CMT2E to switch off the faulty copy of a gene so the healthy copy can take over. In mice, this led to larger nerve fibers and faster nerve signals, though researchers still need a safe way to deliver it to the right nerve cells. CMTA is funding development of CRISPR approaches for other types of CMT too.  

Catherine Illingworth, a CMTA board member and CMT parent, shared her work on gene replacement therapies for CMT4C and CMT1X. These therapies, developed originally via CMTA-supported projects, deliver a working copy of a missing gene to the cells that make myelin. In mice, one dose rebuilt myelin and improved strength and balance. Catherine founded Kylix Bio to move both programs toward human trials, a costly stage that is often underfunded in rare diseases. She encouraged families to share their stories, noting that one late-night TikTok she posted raised more than $500,000 in eight weeks and worked with CMTA to drive this treatment toward a clinical trial. 

CMTA has ‘root cause’ treatments in development across several CMT subtypes. By working to correct or alleviate the original genetic causes of CMT, we hope to stop it in its tracks.   

Targeting shared pathways: Treatments that could help many people with CMT   

Daniel Brennan, Senior Vice President of Corporate and Commercial Strategy, NMD Pharma 

Jordan VerPlank, PhD, Assistant Professor, Uniformed Services University 

Instead of fixing one genetic cause at a time, these approaches target damage and pathways common to many CMT subtypes. Daniel Brennan explained that NMD Pharma’s investigational drug, ignaseclant, eases a natural “brake” on muscles so they can respond better to the weakened nerve signals that are a common feature in CMT. In the company’s Phase 2 trial of 80 people with CMT1 or CMT2, participants saw improvements in grip strength and hand coordination after three weeks, with similar results across both CMT types. 

Jordan VerPlank studies the proteasome, which works like a woodchipper inside cells, breaking down damaged or over-produced proteins. In mouse models of CMT1A and CMT1B, the proteins that cause the disease jam this system. Jordan’s lab has found small molecules that help clear those proteins, which restored myelin and improved nerve signals and movement in mice. With the CMTA’s support, his team is working to move these findings toward people. 

Drugs that target shared pathways have the potential to help all people with CMT, irrespective of the genetic cause. Foundational research to understand the biological pathways affected in CMT and identify targets for treatments has brought us to where we are now, identifying and testing drugs that can make these faulty pathways work better.    

John Svaren, PhD, Cellular and Molecular Neuroscience Core Director & Comparative Biosciences Professor, University of Wisconsin-Madison 

Rachel Salzman, DVM, Chief Executive Officer, Armatus Bio 

Brian Price, PhD, Co-founder & Chief Executive Officer, NeuCore Bio 

Even the most promising treatment won’t work unless it reaches the right cells in our bodies. That’s why CMTA supports four non-viral delivery technology studies in addition to long-running viral vector studies and the Alliance Partner efforts highlighted below. 

  • The challenge: John Svaren explained that natural barriers protect the nerves from infection and inflammation, but they also block many therapies from reaching the cells affected by CMT, which are found in the furthest parts of our peripheral nervous system. 
  • A natural delivery truck: Brian Price shared how NeuCore Bio is repurposing extracellular vesicles, tiny packages that cells naturally use to deliver cargo to each other. Engineered to target the cells that make myelin, they carry cargo that turns down the extra PMP22 that causes CMT1A. In lab tests on human cells, PMP22 dropped by about 25% to 30%. Animal studies are next. 
  • Reaching distant nerves: Rachel Salzman shared that Armatus Bio’s CMT1A therapy, using a viral vector delivery system, given as one injection into the spinal fluid, reached nerves in the arms and legs of mice and monkeys. She said it lowered PMP22 to healthy levels with no signs of toxicity, a finding that could help guide delivery for many CMT subtypes. 
  • These two delivery systems are being tested for CMT1A, but if successful, the cargo could be swapped out and replaced with cargo that works on other subtypes of CMT. We call this a ‘platform approach’. It shows how research in one subtype of CMT can support progress in many others and is a fundamental principle of CMTA’s research strategy.   

Clinical trials: The industry perspective 

Moderator: Sue Bruhn, PhD, Chief Executive Officer, CMTA  

Panelists: Stewart McCallum, MD, Setara Bio; Rachel Thomas, RN, CCRC, Head of Clinical Operations, Elpida Therapeutics; and Daniel Brennan, Senior Vice President of Corporate and Commercial Strategy, NMD Pharma 

Sue led a conversation with three drug developers about where their clinical trial programs stand: 

  • NMD Pharma (CMT1 and CMT2): After encouraging data from the Phase 2 trial, the company is working with the FDA to design the Phase 3 trial of ignaseclant, a twice-daily pill, which it hopes will be its final study before seeking approval. 
  • Elpida Therapeutics (CMT4J): The nonprofit is running a natural history study in parallel with a Phase 1/2 trial of a one-time gene therapy for ages 3 to 20. 
  • Setara Bio (CMT2C): After positive early safety results in healthy volunteers, the company is awaiting FDA clearance to begin a Phase 1b/2 trial in 2C patients. 

Panelists said funding, finding enough participants and the lack of an established FDA path for CMT all slow drug development. Patients can help speed things up by joining natural history studies, sharing their experiences through CMTA-facilitated FDA listening sessions and reaching out about trials even when they’re unsure they qualify. They encouraged attendees to sign up for CMTA’s Patients as Partners in Research program, which helped NMD Pharma recruit to their last trial five months ahead of schedule and supports patient access to all clinical trials running in CMT.

CMTA is actively working to speed up drug development. All the companies on our industry panel worked with CMTA on the recently published document ‘Clinical Development of Therapies for Charcot–Marie–Tooth Disease: Recommendations for Trial Design, Endpoints, and Regulatory Pathways’, to help forge that path through the FDA.  

Across every front, CMTA is pushing research, treatment development and clinical trials forward. We can only do this with the support of our community, every step of the way, because together we are stronger.  

Thank you  

Thank you to everyone who joined us in San Francisco, and to the speakers, panelists, sponsors, volunteers and staff who made the 2026 CMTA Patient & Research Summit possible. 

Missed a session, or want to watch one again? All summit sessions are available on CMTA’s YouTube channel.  

If you missed it, read our Day 1 recap. We hope to see you at next year’s summit!

The information provided here is for informational purposes only and does not constitute medical advice. The CMTA does not endorse any specific products or treatments for CMT. Please consult your doctor before making any healthcare decisions.

Published On: